Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals Inc. (symbol: REGN) is a prominent American biotechnology company headquartered in Westchester County, New York, since its founding in 1988. The core mission of Regeneron is to discover, develop, and commercialize innovative products targeting a range of serious medical conditions. With a diverse portfolio, Regeneron focuses on therapies for eye diseases, cardiovascular conditions, cancer, and inflammatory disorders.
Among its marketed products, Eylea stands out as a treatment for wet age-related macular degeneration and other eye diseases. Praluent is designed to lower LDL cholesterol levels, while Dupixent addresses multiple immunological conditions. In the oncology sector, Libtayo is a key therapy, and Kevzara targets rheumatoid arthritis.
The company is also heavily invested in the development of monoclonal and bispecific antibodies, often in collaboration with Sanofi and other partners. These initiatives include cutting-edge technologies such as RNA interference (RNAi) with Alnylam and CRISPR-based gene editing with Intellia.
Regeneron's recent progress includes significant advancements in its clinical-stage pipeline, which comprises over 35 product candidates. The company's financial health remains robust, supported by strong revenue streams from collaboration with Sanofi and a strategic $3.0 billion share repurchase program authorized by the board.
Latest updates highlight the company's ongoing efforts in gene therapy, particularly in treating genetic deafness and solid tumors. Regeneron's commitment to pioneering genetic medicine and leveraging data insights from the Regeneron Genetics Center® positions it as a leader in the biopharmaceutical industry.
For more information, visit Regeneron Pharmaceuticals.
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced Phase 2 primary analysis results for odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) at the 65th American Society of Hematology (ASH) Annual Meeting. The data showed a 52% objective response rate (ORR) and 31% complete response (CR) in the pivotal Phase 2 trial, with additional positive results from the Phase 1 trial. The primary analysis demonstrated impressive response rates, including in high-risk subgroups, and the potential treatment option for patients with this aggressive blood cancer. Odronextamab is currently under regulatory review for the treatment of R/R DLBCL and R/R FL by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the primary endpoint analysis from the pivotal trial investigating linvoseltamab demonstrated high rates of deep and durable responses in patients with relapsed/refractory multiple myeloma. At a median duration of follow-up of 11 months, an objective response rate of 71% was observed, with 46% achieving a complete response or better. The regimen had a convenient, response-adapted administration schedule that enabled deep responders to go from every two-week to every four-week dosing. All patients treated with 200 mg experienced an adverse event, including 85% who experienced Grade ≥3 adverse events. Deaths due to treatment-emergent AEs on-treatment or within 30 days post last dose occurred in 14 patients (12%).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) presented encouraging Phase 1 dose-escalation data for REGN5668 (MUC16xCD28) in combination with Libtayo (cemiplimab) at the ESMO IO Congress 2023. Initial results show early clinical activity in patients with recurrent ovarian cancer, with a 21% stable disease rate and a 59% target lesion reduction from baseline in one patient. The combination demonstrated an acceptable safety profile with fatigue, nausea, and pain as the most common treatment-related adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and webcast on December 14, 2023, to provide an update on its hematology portfolio. This follows data updates presented at the 65th ASH Annual Meeting and Exposition. The webcast can be accessed on the company's website, and a replay will be available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi's NOTUS trial for Dupixent in patients with COPD with type 2 inflammation showed a 34% reduction in exacerbations, rapid lung function improvement, and plans for a supplemental BLA submission by end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to participate in Piper Sandler 35th Annual Healthcare Conference on November 28, 2023. The webcast will be available on the company's website, with a replay and transcript accessible for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is increasing and extending its commitment as the title sponsor of the Regeneron International Science and Engineering Fair (ISEF), the world’s largest high school science and engineering competition, with a total investment of approximately $34 million over a five-year period. Established in 1950, Regeneron ISEF gives young scientists a global stage to share their outstanding STEM research and compete for nearly $8 million in awards, prizes, and scholarships. The renewed sponsorship builds on Regeneron and the Society's long-standing partnership to advance STEM education, including through Regeneron's $100 million, ten-year commitment to the Regeneron Science Talent Search (STS), the nation’s oldest and most prestigious high school science and mathematics competition. The increased investment will raise the top ISEF award, the George D. Yancopoulos Innovator Award, to $100,000, the two second place awards, the Regeneron Young Scientist Awards, to $75,000 each, and increase all category awards by 20 percent. Since assuming title sponsorship in 2019, Regeneron ISEF has welcomed over 5,000 high school students representing 64 countries and distributed a total of nearly $22 million in awards, prizes, and scholarships to the top young scientists in the world.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals will be sharing new and updated data from its hematology pipeline at the American Society of Hematology (ASH) Annual Meeting. The data includes research on six investigational medicines for eight difficult-to-treat blood cancers and disorders. Key presentations will focus on odronextamab in follicular lymphoma and diffuse large B-cell lymphoma, as well as linvoseltamab in multiple myeloma. Odronextamab is currently under regulatory review, and linvoseltamab will present primary endpoint results with longer follow-up.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.23%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. reported a 15% increase in revenues to $3.36 billion in the third quarter of 2023. Dupixent global net sales increased by 33% to $3.10 billion, while U.S. net sales for EYLEA and EYLEA HD were $1.49 billion. The company also announced the FDA approval of EYLEA HD for wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, as well as the FDA acceptance for priority review of odronextamab for follicular lymphoma and diffuse large B-cell lymphoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.48%
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. will present long-term outcomes and new analyses of pivotal clinical data for EYLEA HD (aflibercept) Injection 8 mg at the American Academy of Ophthalmology annual meeting. The presentations will highlight the durability of visual improvements and consistent safety of EYLEA HD across extended dosing intervals and patient characteristics. Notable presentations include positive two-year results from trials in wet age-related macular degeneration and diabetic macular edema, as well as subgroup data and safety analysis. EYLEA HD is being jointly developed by Regeneron and Bayer AG.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.48%
Tags
FAQ
What is the current stock price of Regeneron Pharmaceuticals (REGN)?
The current stock price of Regeneron Pharmaceuticals (REGN) is $701.85 as of December 20, 2024.
What is the market cap of Regeneron Pharmaceuticals (REGN)?
The market cap of Regeneron Pharmaceuticals (REGN) is approximately 77.4B.
What types of diseases does Regeneron Pharmaceuticals focus on?
Regeneron focuses on eye diseases, cardiovascular conditions, cancer, and inflammatory disorders.
What are some of Regeneron's key products?
Key products include Eylea for eye diseases, Praluent for lowering LDL cholesterol, Dupixent for immunology, Libtayo for oncology, and Kevzara for rheumatoid arthritis.
Who are some of Regeneron's notable collaborators?
Regeneron collaborates with Sanofi, Alnylam, and Intellia on various projects, including monoclonal and bispecific antibodies, RNAi, and CRISPR-based gene editing.
What recent financial steps has Regeneron taken?
Regeneron has initiated a $3.0 billion share repurchase program and reported strong financial performance in the first quarter of 2024.
How does Regeneron leverage genetic medicine?
Regeneron utilizes data-powered insights from the Regeneron Genetics Center® and employs proprietary technologies like VelociSuite® to advance drug development.
What is the significance of Eylea in Regeneron's product portfolio?
Eylea is a crucial product for treating wet age-related macular degeneration and other eye diseases, contributing significantly to Regeneron's revenue.
What advancements has Regeneron made in gene therapy?
Regeneron is progressing in gene therapy for genetic deafness and solid tumors, showcasing promising early results in clinical trials.
What is Dupixent used for?
Dupixent is used in treating various immunological conditions and has shown significant growth since its launch, treating over 850,000 patients.
What technologies does Regeneron use for drug development?
Regeneron uses proprietary technologies such as VelociSuite®, which includes platforms for producing optimized human antibodies and bispecific antibodies.
How does Regeneron contribute to scientific discovery?
Regeneron pushes the boundaries of scientific discovery with pioneering genetic medicine platforms and data insights, aiming to develop transformative therapies.
Regeneron Pharmaceuticals Inc
Nasdaq:REGN
REGN Rankings
REGN Stock Data
77.39B
106.22M
1.56%
90.64%
1.63%
Biotechnology
Pharmaceutical Preparations
United States of America
TARRYTOWN